$109 Million is the total value of BML Capital Management, LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | VISTAGEN THERAPEUTICS INC | $524,000 | – | 100,000 | +100.0% | 0.48% | – | |
| QQQ | New | INVESCO QQQ TRput | $443,880 | – | 108 | +100.0% | 0.41% | – |
| New | NEOLEUKIN THERAPEUTICS INC | $389,723 | – | 98,664 | +100.0% | 0.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-10-23
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR SER TR | 4 | Q3 2023 | 16.9% |
| ADVERUM BIOTECHNOLOGIES INC | 4 | Q3 2023 | 7.4% |
| ELIEM THERAPEUTICS INC | 4 | Q3 2023 | 6.4% |
| ATHIRA PHARMA INC | 4 | Q3 2023 | 4.9% |
| ASTROTECH CORP | 4 | Q3 2023 | 2.8% |
| ARCA BIOPHARMA INC | 4 | Q3 2023 | 1.9% |
| FORTE BIOSCIENCES INC | 4 | Q3 2023 | 1.6% |
| VERRICA PHARMACEUTICALS INC | 4 | Q3 2023 | 2.9% |
| PASSAGE BIO INC | 4 | Q3 2023 | 1.7% |
| RETRACTABLE TECHNOLOGIES INC | 4 | Q3 2023 | 1.0% |
View BML Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-04-24 |
| 13F-HR | 2024-04-23 |
| 13F-HR/A | 2024-02-02 |
| 13F-HR | 2024-01-30 |
| 13F-HR | 2023-10-23 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-13 |
View BML Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.